Publicité
Publicité

CUE

CUE logo

Cue Biopharma, Inc.

0.36
USD
Sponsorisé
-0.03
-8.63%
09 janv., 15:58 UTC -5
Fermé
exchange

Après-marché

0.37

+0.01
+3.90%

CUE Rapports sur les bénéfices

Ratio de surprise positive

CUE a dépassé 18 des 29 dernières estimations.

62%

Prochain rapport

Date du prochain rapport
30 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.52M
/
-$0.10
Variation implicite de Q3 25 (Revenue/ EPS)
+17.50%
/
+42.86%
Variation implicite de Q4 24 (Revenue/ EPS)
+60.22%
/
-23.08%

Cue Biopharma, Inc. earnings per share and revenue

On 12 nov. 2025, CUE reported earnings of -0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 25.77% surprise. Revenue reached 2.15 million, compared to an expected 2.31 million, with a -7.07% difference. The market reacted with a -7.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analystes forecast an EPS of -0.10 USD, with revenue projected to reach 2.52 million USD, implying an hausse of 42.86% EPS, and hausse of 17.50% in Revenue from the last quarter.
FAQ
For Q3 2025, Cue Biopharma, Inc. reported EPS of -$0.07, beating estimates by 25.77%, and revenue of $2.15M, -7.07% below expectations.
The stock price moved down -7.19%, changed from $0.67 before the earnings release to $0.62 the day after.
The next earning report is scheduled for 30 mars 2026.
Based on 3 analystes, Cue Biopharma, Inc. is expected to report EPS of -$0.10 and revenue of $2.52M for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité